Probiotix Health PLC - Change of Registered Office
Announcement provided by
ProBiotix Health Plc · PBX19/04/2022 09:08
ProBiotix Health plc
("ProBiotix Health" or the "Company")
Change of registered office
ProBiotix Health plc (AQSE: PBX), a life sciences business developing probiotics to tackle cardiovascular disease and other lifestyle conditions, announces that it has changed its registered address to: First Floor, Zucchi Suite, Nostell Business Estate,
All formal notices and general correspondence should be sent to the new address.
For further information, please contact:
|
Probiotix Health plc |
Contact via Walbrook below |
|
|
Stephen O'Hara, Chief Executive |
|
|
|
|
|
|
|
Peterhouse Capital Limited |
Tel: 020 7469 0930 |
|
|
Mark Anwyl (AQSE Corporate Adviser) |
|
|
|
Duncan Vasey (Broker) |
|
|
|
|
|
|
|
Walbrook PR Ltd |
Mob: 07876 741 001 or probiotix@walbrookpr.com |
|
|
Anna Dunphy |
|
|
About ProBiotix Health plc
ProBiotix Health develops probiotics (live microbes that, when ingested, can alter the composition of the microbiome and improve human health) to tackle cardiovascular disease and other lifestyle conditions which are affecting growing numbers of people across the world.
ProBiotix Health's cholesterol reducing probiotic, Lactobacillus plantarum ECGC13110402 ("LP-LDL®), is manufactured in pharmaceutical GMP-certified facilities and protected worldwide by in the region of 5 patent families, comprising 27 patents and pending patent applications, and 22 trademarks.
RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
